Evidence map›Paper›PMID 39201479›Full record

ArticleInternational journal of molecular sciences2024

LC/MS-Based Untargeted Lipidomics Reveals Lipid Signatures of Sarcopenia.

Qianwen Yang, Zhiwei Zhang, Panpan He, Xueqian Mao, Xueyi Jing, Ying Hu, Lipeng Jing

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianwen YangInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Zhiwei ZhangInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Panpan HeInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Xueqian MaoInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Xueyi JingInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Ying HuInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.
Lipeng JingInstitute of Epidemiology and Statistics, School of Public Health, Lanzhou University, Lanzhou 730000, China.ORCID 0000-0003-1856-0324

Funding

Fundamental Research Funds for the Central Universities lzujbky-2023-40Gansu Province Science Foundation for Youths 21JR7RA507National Natural Science Foundation of China 82003525
6 · The paper itself

Abstract

Sarcopenia, a multifactorial systemic disorder, has attracted extensive attention, yet its pathogenesis is not fully understood, partly due to limited research on the relationship between lipid metabolism abnormalities and sarcopenia. Lipidomics offers the possibility to explore this relationship. Our research utilized LC/MS-based nontargeted lipidomics to investigate the lipid profile changes as-sociated with sarcopenia, aiming to enhance understanding of its underlying mechanisms. The study included 40 sarcopenia patients and 40 control subjects matched 1:1 by sex and age. Plasma lipids were detected and quantified, with differential lipids identified through univariate and mul-tivariate statistical analyses. A weighted correlation network analysis (WGCNA) and MetaboAna-lyst were used to identify lipid modules related to the clinical traits of sarcopenia patients and to conduct pathway analysis, respectively. A total of 34 lipid subclasses and 1446 lipid molecules were detected. Orthogonal partial least squares discriminant analysis (OPLS-DA) identified 80 differen-tial lipid molecules, including 38 phospholipids. Network analysis revealed that the brown module (encompassing phosphatidylglycerol (PG) lipids) and the yellow module (containing phosphati-dylcholine (PC), phosphatidylserine (PS), and sphingomyelin (SM) lipids) were closely associated with the clinical traits such as maximum grip strength and skeletal muscle mass (SMI). Pathway analysis highlighted the potential role of the glycerophospholipid metabolic pathway in lipid me-tabolism within the context of sarcopenia. These findings suggest a correlation between sarcopenia and lipid metabolism disturbances, providing valuable insights into the disease's underlying mechanisms and indicating potential avenues for further investigation.

Indexed as

Lipid MetabolismLipidomicsLipidsSarcopeniaAgedCase-Control StudiesChromatography, LiquidFemaleHumansMaleMass SpectrometryMiddle AgedMuscle, SkeletalLipidsLC/MSlipid signaturessarcopeniauntargeted lipidomics

Identifiers

PMID39201479
PMCPMC11354784

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.